Openbookopenbook
Equity
NAMS
+0.0 · +0.00%
USD · NASDAQ

NewAmsterdam Pharma Company N.V. Ordinary Shares(NAMS) Stock Analysis | Healthcare

USD --+0.00%
Reward40Moderate
Risk19Low
75%Data
Revenue down 81% YoY
Earnings Deterioration
Market Cap:3.03Bn
ⓘ
Reward Rating
40
Moderate
Reward Assessment
75% data coverage
Bottom 10% of stocksView factors
ⓘ
Risk Rating
19
Low
Risk Assessment
3 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on NAMS to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for NAMS, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $51.54.

What is NewAmsterdam Pharma Company N.V. Ordinary Shares?

, a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.

NAMS · Verdict

Moderate reward · low risk

NAMS stands out on volatility and balance sheet, but watch the valuation signal.

Based on 88% data coverage

NAMS · Verdict

What’s working & what to watch

Strengths 2

  • Volatility95/100

    Top decile vs peers

  • Balance sheet93/100

    Current ratio 7.88

Watchouts 4

  • Valuation28/100

    Below average

  • Cash flow29/100

    -658% free-cash-flow margin

  • Profitability32/100

    -906% net margin · -37% ROE

  • Growth42/100

    Rev -39.7% CAGR · earnings +108.0%

Model-based scoring. For information only — not financial advice.

What is NewAmsterdam Pharma Company N.V. Ordinary Shares?

, a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 3.03B.

Financial Highlights

Investment Breakdown

Growth
Growth trend is developing — watch for revenue consistency over upcoming quarters.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (40)

The scoring profile indicates limited reward potential at this time, with momentum and size offering the most support. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

TARSMid Cap / 3B market cap
Tarsus Pharmaceuticals Inc
Compare
IRONMid Cap / 3.1B market cap
Disc Medicine Inc.
Compare
BEAMMid Cap / 3.1B market cap
Beam Therapeutics Inc
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap3.03B
P/E RatioN/A
Dividend YieldN/A
Beta0.11
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
6816,512 shares
$26.0M
0
6-9months
13650,421 shares
$22.4M
0
9-12months
0
1660 shares
$16k
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.